Page last updated: 2024-08-25

rosiglitazone and vorapaxar

rosiglitazone has been researched along with vorapaxar in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cutler, DL; Hanson, ME; Kantesaria, B; Kosoglou, T; Kumar, B; Schiller, JE; Sisk, CM; Statkevich, P	1

Trials

1 trial(s) available for rosiglitazone and vorapaxar

Article	Year
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone. Clinical pharmacology in drug development, 2015, Volume: 4, Issue:1 Topics: Adolescent; Adult; Area Under Curve; Biotransformation; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Female; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Lactones; Male; Metabolic Clearance Rate; Middle Aged; North Dakota; Platelet Aggregation Inhibitors; Pyridines; Receptor, PAR-1; Rosiglitazone; Therapeutic Equivalency; Thiazolidinediones; Young Adult	2015

Article

Year

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.

Clinical pharmacology in drug development, 2015, Volume: 4, Issue:1

Topics: Adolescent; Adult; Area Under Curve; Biotransformation; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Female; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Lactones; Male; Metabolic Clearance Rate; Middle Aged; North Dakota; Platelet Aggregation Inhibitors; Pyridines; Receptor, PAR-1; Rosiglitazone; Therapeutic Equivalency; Thiazolidinediones; Young Adult

2015